Replies to post #185709 on Arrayit Corporation (ARYC)

[StockDetective]

Your welcome.
“Separately, the CDC said it is working on its own version of a blood test to find out who may have immunity to COVID-19. This is a potential game-changer in the battle to contain infections and get the economy back on track.” “Several academic laboratories and medical companies are rushing to produce these blood tests, which can quickly identify disease-fighting antibodies in people who already have been infected but may have had mild symptoms or none at all. This is different from the current, sometimes hard-to-come-by diagnostic tests that draw on a nasal swab to confirm active infection.” “Ultimately, this (antibody test) might help us figure out who can get the country back to normal,” Florian Krammer, a professor in vaccinology at Mount Sinai’s Icahn School of Medicine, told Reuters. “People who are immune could be the first people to go back to normal life and start everything up again.” “The CDC has not yet given a timetable for the antibody test.” http://www.efreenews.com/a/cdc-to-launch-surveillance-and-data-collection-system-to-map-covid-19-spread

[StockDetective]

This is also very interesting. “Miniaturized, Multiplexed, Parallelized, and Simultaneous Auto-Antibody Measurements for Serodiagnosis of Disease”
“Arrayit’s microarray platform is suitable assay format for the serodiagnosis of diseases and is suitable for clinical use. The miniaturization, multiplexing and parallelism along with the ability to simultaneously detect up to 4 Ig antibodies (i.e. IgG and IgM) in a single assay have important advantages in throughput, convenience, cost and sensitivity.”
“Processing Protocol
1. Intended use
Serum based immunoassays using antigens as capture agents, designed to identify, measure and report levels of immunoglobulin proteins present in human serum, plasma or whole blood.”


https://arrayit.blogspot.com/2013/02/tech-note-miniaturized-multiplexed.html?m=1